Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07697-y ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Siqi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China. Hauptthemen laut MEDLINE: 3-Iodobenzylguanidine, Neuroblastoma, Positron Emission Tomography Computed Tomography, Fluorides. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, Xicheng District Science and Technology Special Project Plan.
Abstract (Originalsprache)
PURPOSE: To evaluate and compare the diagnostic performance of fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide (18F-AlF-NOTATATE) PET/CT and iodine-123 Metaiodobenzylguanidine (123I-MIBG) scintigraphy with SPECT/CT in detecting recurrent high-risk neuroblastoma (HR-NB) after complete response (CR), and to evaluate their impact on clinical decision-making. METHODS: This retrospective study included 68 HR-NB patients (67 with confirmed recurrences, 1 without recurrence) who underwent 18F-AlF-NOTATATE PET/CT and 123I-MIBG scintigraphy with SPECT/CT within 7 days. Imaging findings were analyzed for sensitivity, lesion patterns, anatomical locations, spatial distribution, and semiquantitative Curie scores. The impact on clinical management was evaluated by comparing actual versus hypothetical treatment decisions. Recurrence was confirmed using a composite reference standard (histopathology or ≥ 6-month of imaging/clinical follow-up). RESULTS: 18F-AlF-NOTATATE PET/CT demonstrated numerically higher sensitivity than 123I-MIBG scintigraphy with SPECT/CT (97.0% vs. 88.2%). The combined use of both modalities achieved 100% sensitivity, a statistically significant improvement over either single modality (p < 0.001). Recurrences predominantly exhibited focal/mixed patterns (94.0%) and distant metastases (82.0%; p < 0.001). 18F-AlF-NOTATATE PET/CT yielded significantly higher Curie scores (p = 0.002). Clinically, 18F-AlF-NOTATATE PET/CT influenced therapeutic decisions in 37.5% of cases, versus 5% for 123I-MIBG scintigraphy with SPECT/CT alone. Combined imaging affected management in 58.8% of cases (72.5% therapeutic shifts). CONCLUSION: 18F-AlF-NOTATATE PET/CT provides critical complementary value to 123I-MIBG scintigraphy with SPECT/CT. It provides a numerical sensitivity benefit, mitigates MIBG non-avidity limitations, and informs clinical decision-making. The combined use of both imaging modalities achieves 100% sensitivity, supporting the integration of this dual-modality approach into HR-NB surveillance protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
- Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, China.
- Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, 250117, China. xrsun@sdfmu.edu.cn.
- Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China. yangjigang@ccmu.edu.cn.
ORCID-Profile: Jigang Yang
Förderung
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
- Xicheng District Science and Technology Special Project Plan
- Beijing Friendship Hospital Seed Project of Capital Medical University
Zitieren
APA
Li, S., Liu, Y., Liu, J., Sang, B., Xu, Y., Sun, X., & Yang, J. (2025). Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07697-y
Vancouver
Li S, Liu Y, Liu J, Sang B, Xu Y, Sun X, et al. Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07697-y
BibTeX
@article{Li2025,
author = {Li, Siqi and Liu, Yuxuan and Liu, Jun and Sang, Baojun and Xu, Yanfeng and Sun, Xiaorong and Yang, Jigang},
title = {Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07697-y}
}
EUVIMED